Under the medical supervision of Dr
Frequently Asked Questions Lower dose options, such as 20 mg, are generally preferred in early-stage or dose-escalation research protocols
Patients should be counselled to avoid such exposures unless the product information specifically states otherwise
Prescribed as Wegovy or Ozempic, its one of the few medicines to have predictable results, with clinical trials showing weight loss of up to 10-15% in about a year
NICE's overarching guidance on obesity management emphasises that pharmacological treatment should always be used alongside dietary, behavioural, and physical activity interventions
GLP-1s may not be suitable for people who: Have a history of pancreatitis Have certain thyroid conditions (e.g., medullary thyroid cancer) Are pregnant or breastfeeding (depending on the specific medication) Have severe gastrointestinal conditions, like gastroparesis GLP-1 receptor agonists, including Tirzepatide, have been shown to lead to significant weight loss, with many people losing 10-15% of their body weight over time
